Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.

Miyahira AK, Den RB, Carlo MI, de Leeuw R, Hope TA, Karzai F, McKay RR, Salami SS, Simons JW, Pienta KJ, Soule HR.

Prostate. 2019 Feb;79(3):244-258. doi: 10.1002/pros.23729. Epub 2018 Oct 31. Review.

PMID:
30381857
2.

Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?

Faiena I, Holden S, Cooperberg MR, Holden S, Soule HR, Simons JW, Morgan TM, Penson DF, Morgans AK, Hussain M.

J Clin Oncol. 2018 Apr 1;36(10):937-941. doi: 10.1200/JCO.2017.76.4050. Epub 2018 Feb 5. No abstract available.

3.

Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.

Miyahira AK, Cheng HH, Abida W, Ellis L, Harshman LC, Spratt DE, Simons JW, Pienta KJ, Soule HR.

Prostate. 2017 Nov;77(15):1478-1488. doi: 10.1002/pros.23424. Epub 2017 Sep 18. Review.

4.

Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.

Miyahira AK, Roychowdhury S, Goswami S, Ippolito JE, Priceman SJ, Pritchard CC, Sfanos KS, Subudhi SK, Simons JW, Pienta KJ, Soule HR.

Prostate. 2017 Feb;77(2):123-144. doi: 10.1002/pros.23260. Epub 2016 Sep 28. Review.

PMID:
27679977
5.

The 22nd annual prostate cancer foundation scientific retreat report.

Miyahira AK, Simons JW, Soule HR.

Prostate. 2016 Sep;76(12):1037-52. doi: 10.1002/pros.23193. Epub 2016 Jun 8. Review.

PMID:
27272144
6.

Oslerian Genomics for Prostate Cancer Oncology.

Meng JX, Levine R, Simons JW.

Oncology (Williston Park). 2016 Feb;30(2):200, 202. No abstract available.

7.

Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.

Miyahira AK, Lang JM, Den RB, Garraway IP, Lotan TL, Ross AE, Stoyanova T, Cho SY, Simons JW, Pienta KJ, Soule HR.

Prostate. 2016 Feb;76(2):125-39. doi: 10.1002/pros.23107. Epub 2015 Oct 19. Review.

8.

The 21st Annual Prostate Cancer Foundation Scientific Retreat report.

Miyahira AK, Simons JW, Soule HR.

Prostate. 2015 Aug 1;75(11):1119-28. doi: 10.1002/pros.22993. Epub 2015 Apr 20. Erratum in: Prostate. 2016 May;76(6):609-10.

PMID:
25893521
9.

Prostate cancer immunotherapy: beyond immunity to curability.

Simons JW.

Cancer Immunol Res. 2014 Nov;2(11):1034-43. doi: 10.1158/2326-6066.CIR-14-0174. Review.

10.

Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.

Miyahira AK, Kissick HT, Bishop JL, Takeda DY, Barbieri CE, Simons JW, Pienta KJ, Soule HR.

Prostate. 2015 Mar 1;75(4):337-47. doi: 10.1002/pros.22920. Epub 2014 Oct 30. Review.

PMID:
25358693
11.

The 20th Annual Prostate Cancer Foundation Scientific Retreat report.

Miyahira AK, Simons JW, Soule HR.

Prostate. 2014 Jun;74(8):811-9. doi: 10.1002/pros.22808. Epub 2014 Apr 9.

PMID:
24719035
12.
13.

Tracking the clonal origin of lethal prostate cancer.

Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S.

J Clin Invest. 2013 Nov;123(11):4918-22. doi: 10.1172/JCI70354. Epub 2013 Oct 25.

14.

The 19th annual Prostate Cancer Foundation scientific retreat.

Walia G, Pienta KJ, Simons JW, Soule HR.

Cancer Res. 2013 Aug 15;73(16):4988-91. doi: 10.1158/0008-5472.CAN-12-4576. Epub 2013 Mar 27.

15.

The 17th Annual Prostate Cancer Foundation scientific retreat: meeting report.

Ericson KR, Simons JW, Soule HR.

Prostate. 2011 Nov;71(15):1616-20. doi: 10.1002/pros.21378. Epub 2011 Mar 10.

PMID:
21394742
16.

The genomic complexity of primary human prostate cancer.

Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY, Kantoff PW, Chin L, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA.

Nature. 2011 Feb 10;470(7333):214-20. doi: 10.1038/nature09744.

17.

The Prostate Cancer Foundation 16th Annual Scientific Retreat: meeting report.

Rhodes KE, Simons JW, Soule HR.

Prostate. 2010 Jun 1;70(8):916-20. doi: 10.1002/pros.21127.

PMID:
20166134
19.

SEPT9_v1 up-regulates hypoxia-inducible factor 1 by preventing its RACK1-mediated degradation.

Amir S, Wang R, Simons JW, Mabjeesh NJ.

J Biol Chem. 2009 Apr 24;284(17):11142-51. doi: 10.1074/jbc.M808348200. Epub 2009 Feb 26.

20.

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.

Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J, Small EJ.

Cancer. 2008 Sep 1;113(5):975-84. doi: 10.1002/cncr.23669.

21.

Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells.

Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, O'Regan RM.

Cancer Res. 2008 Apr 1;68(7):2479-88. doi: 10.1158/0008-5472.CAN-07-2559. Erratum in: Cancer Res. 2008 May 15;68(10):4012.

22.

The current state of preclinical prostate cancer animal models.

Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL.

Prostate. 2008 May 1;68(6):629-39. doi: 10.1002/pros.20726.

23.

Quantum dots: emerging applications in urologic oncology.

Shi C, Zhu Y, Cerwinka WH, Zhau HE, Marshall FF, Simons JW, Nie S, Chung LW.

Urol Oncol. 2008 Jan-Feb;26(1):86-92. doi: 10.1016/j.urolonc.2007.03.018. Review.

PMID:
18190836
24.

Epigenetic hereditary transcription profiles II, aging revisited.

Simons JW.

Biol Direct. 2007 Dec 28;2:39. doi: 10.1186/1745-6150-2-39.

25.

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.

Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW.

Clin Cancer Res. 2007 Jul 1;13(13):3883-91.

26.

Nanotechnology for targeted cancer therapy.

Wang MD, Shin DM, Simons JW, Nie S.

Expert Rev Anticancer Ther. 2007 Jun;7(6):833-7. Review.

PMID:
17555393
27.

Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry.

Xing Y, Chaudry Q, Shen C, Kong KY, Zhau HE, Chung LW, Petros JA, O'Regan RM, Yezhelyev MV, Simons JW, Wang MD, Nie S.

Nat Protoc. 2007;2(5):1152-65.

PMID:
17546006
28.

Nanotechnology applications in cancer.

Nie S, Xing Y, Kim GJ, Simons JW.

Annu Rev Biomed Eng. 2007;9:257-88. Review.

PMID:
17439359
29.

Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model.

Kang SH, Cho HT, Devi S, Zhang Z, Escuin D, Liang Z, Mao H, Brat DJ, Olson JJ, Simons JW, Lavallee TM, Giannakakou P, Van Meir EG, Shim H.

Cancer Res. 2006 Dec 15;66(24):11991-7.

30.
31.

Hypoxia-inducible factor-1 in human breast and prostate cancer.

Kimbro KS, Simons JW.

Endocr Relat Cancer. 2006 Sep;13(3):739-49. Review.

PMID:
16954428
32.

Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.

Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S, Mulligan R, Nelson WG.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3394-401.

33.

Hereditary profiles of disorderly transcription?

Simons JW.

Biol Direct. 2006 Apr 2;1:9.

34.
35.

Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells.

Chen C, Sun X, Guo P, Dong XY, Sethi P, Cheng X, Zhou J, Ling J, Simons JW, Lingrel JB, Dong JT.

J Biol Chem. 2005 Dec 16;280(50):41553-61. Epub 2005 Oct 13.

36.

KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line.

Chen C, Benjamin MS, Sun X, Otto KB, Guo P, Dong XY, Bao Y, Zhou Z, Cheng X, Simons JW, Dong JT.

Int J Cancer. 2006 Mar 15;118(6):1346-55.

37.

Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer.

Sun X, Frierson HF, Chen C, Li C, Ran Q, Otto KB, Cantarel BL, Vessella RL, Gao AC, Petros J, Miura Y, Simons JW, Dong JT.

Nat Genet. 2005 Apr;37(4):407-12. Epub 2005 Mar 6. Erratum in: Nat Genet. 2005 Jun;37(6):652. Cantarel, Brandi M [corrected to Cantarel, Brandi L].

PMID:
15750593
38.

Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells.

Chen C, Sun X, Ran Q, Wilkinson KD, Murphy TJ, Simons JW, Dong JT.

Oncogene. 2005 May 5;24(20):3319-27.

PMID:
15735697
39.

In vivo molecular and cellular imaging with quantum dots.

Gao X, Yang L, Petros JA, Marshall FF, Simons JW, Nie S.

Curr Opin Biotechnol. 2005 Feb;16(1):63-72. Review.

PMID:
15722017
40.

Exploitation of the HIF axis for cancer therapy.

Escuin D, Simons JW, Giannakakou P.

Cancer Biol Ther. 2004 Jul;3(7):608-11. Epub 2004 Jul 29. Review.

PMID:
15197342
41.

HIF at the crossroads between ischemia and carcinogenesis.

Paul SA, Simons JW, Mabjeesh NJ.

J Cell Physiol. 2004 Jul;200(1):20-30. Review.

PMID:
15137054
42.

Novel therapeutic strategies for androgen-independent prostate cancer: an update.

Assikis VJ, Simons JW.

Semin Oncol. 2004 Apr;31(2 Suppl 4):26-32. Review.

PMID:
15124131
43.

Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis.

Zhong H, Semenza GL, Simons JW, De Marzo AM.

Cancer Detect Prev. 2004;28(2):88-93.

PMID:
15068831
44.

Signal transduction and myeloma: new targets, new hope.

Lonial S, Waller EK, Simons JW, Heffner LT Jr.

Cancer Biol Ther. 2003 Jul-Aug;2(4):310-9. Review.

PMID:
14508098
45.

Chemical processing as a tool to generate ovalbumin variants with changed stability.

Kosters HA, Broersen K, de Groot J, Simons JW, Wierenga P, de Jongh HH.

Biotechnol Bioeng. 2003 Oct 5;84(1):61-70.

PMID:
12910544
46.

Replicative oncolytic adenoviruses in multimodal cancer regimens.

Post DE, Khuri FR, Simons JW, Van Meir EG.

Hum Gene Ther. 2003 Jul 1;14(10):933-46. Review.

PMID:
12869212
47.
48.

Genomic medicines for oncology: early lessons.

Simons JW.

J Med Assoc Ga. 2003 Winter-Spring;92(1):35-8. Review. No abstract available.

PMID:
12743904
49.

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P.

Cancer Cell. 2003 Apr;3(4):363-75.

50.

Dibenzoylmethane, a natural dietary compound, induces HIF-1 alpha and increases expression of VEGF.

Mabjeesh NJ, Willard MT, Harris WB, Sun HY, Wang R, Zhong H, Umbreit JN, Simons JW.

Biochem Biophys Res Commun. 2003 Mar 28;303(1):279-86.

PMID:
12646199

Supplemental Content

Loading ...
Support Center